AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02756676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intensive Rehabilitation Treatment (MIRT)
Description: MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle- stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in daily living activities. The last session includes one hour of speech therapy.
Study NCT02693041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
Study NCT01702103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Study NCT01702103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Study NCT03514667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nanomicielle curcumin
Description: Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
Study NCT03514667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
Study NCT00230009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Study NCT01404702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 4 mg/m2/dose given iv on day 0 of every 28 day cycle
Study NCT01404702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Dose Level 1: 3 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle
Study NCT04050722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensodyne Repair and Protect
Description: Participants will brush their teeth with Sensodyne Repair and Protect (containing 0.454% stannous fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
Study NCT04050722 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colgate Cavity Protection
Description: Participants will brush their teeth with Colgate Cavity Protection repair and protect (containing sodium fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
Study NCT01368549 — intervention group
Intervention type: OTHER
Intervention: Metanx® (a medical food)
Description: Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
Study NCT03918187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
Study NCT03918187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
Study NCT03918187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
Study NCT01219153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended high dose letrozole regimen /GnRH antagonist protocol
Description: Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
Study NCT01219153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short low dose letrozole regimen /GnRH antagonist protocol
Description: Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration .
Study NCT02693041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
Study NCT00889512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luveris fixed dose
Description: Luveris 75IU daily throughout ovarian stimulation
Study NCT00889512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris increasing dose
Description: Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
Study NCT01051336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TARIS Placebo
Study NCT01051336 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Study NCT01937260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
Study NCT00801229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vyvanse
Description: Vyvanse 30, 50, or 70 mg daily
Study NCT00801229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30, 50, 70 mg daily
Study NCT02930902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02930902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02930902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02930902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT02930902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: Given IV
Study NCT02930902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Given IV
Study NCT02930902 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT02930902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02930902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of tumor
Study NCT02930902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of tumor
Study NCT04044339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-5202
Description: Study Drug to be administered orally
Study NCT02997033 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01448018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 3 monthly intravitreous injection as soon as possible after the inclusion
Study NCT01448018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemodilution
Description: hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
Study NCT04061603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adagio AF Cryoablation System (iCLAS™)
Description: Endovascular ablation of the left and right atrium
Study NCT02153944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 40 mg was given orally during study visit
Study NCT02153944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate 20mg was given orally during study visit
Study NCT02153944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given orally during study visit
Study NCT00994331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: non surgical procedure to open blocked coronary arteries
Study NCT03790826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cystoscopy
Description: Comparison of bladder mucosa via cystoscopy.
Study NCT02777125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metered Dose Inhaler
Description: A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.
Study NCT02777125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breath Actuated Nebulizer
Description: The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
Study NCT01533246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: Oral Linsitinib 150mg, twice a day, days 1- 28
Study NCT01533246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04044339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered orally
Study NCT03157804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically Engineered Hematopoietic Stem/Progenitor Cells
Description: Undergo infusion of genetically modified hematopoietic progenitor cell therapy
Study NCT03157804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03157804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SC)
Study NCT03157804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC
Study NCT03157804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Study NCT02567513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplement Intervention
Description: Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
Study NCT02567513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snack Intervention
Description: Snacks given twice/day, 5 days/week for 24 weeks by research staff.
Study NCT02018289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triclosan coated suture
Description: Suture of the abdominal wall with triclosan coated suture
Study NCT01905878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Study NCT00654082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
Study NCT00654082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
Study NCT00370916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-initiated medication reconciliation
Description: Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
Study NCT00370916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-initiated medication reconciliation
Description: Pharmacist performed and documented medication reconciliation
Study NCT03223337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daprodustat (GSK1278863)
Description: Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
Study NCT03223337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat (GSK1278863)
Description: Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
Study NCT01183949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT7519M
Description: Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m\^2/dose and will be increased to 27mg/m\^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose.
Study NCT02018289 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No triclosan
Description: Suture of the abdominal wall with suture without triclosan coat
Study NCT00654069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets every 6 hours for 48 hours
Study NCT00654069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acurox 5/30 mg
Description: 2 tablets every 6 hours for 48 hours
Study NCT00654069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acurox 7.5/30
Description: 2 tablets every 6 hours for 48 hours
Study NCT00003724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure
Study NCT03764722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP \<90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months.
Study NCT02271308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-resistance elastic band training
Description: The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
Study NCT02781103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided imagery plus active tDCS
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
Study NCT02781103 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Guided imagery plus Sham tDCS
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
Study NCT00889343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
Study NCT00889343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
Study NCT00889343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin or Irinotecan
Description: Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
Study NCT00889343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin or Irinotecan
Description: Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
Study NCT00889343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
Study NCT00889343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
Study NCT00889343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
Study NCT01183949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
Study NCT02813291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.